HIV/AIDS Clinical Trial
— IBIS-HealthOfficial title:
Innovative Incentive Strategies for Sustainable HIV Testing and Antiretroviral Treatment
Verified date | February 2022 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The success of combination HIV prevention efforts, including HIV treatment as prevention, hinges on universal, routine HIV testing with effective treatment after HIV diagnosis. The proposed study will evaluate the comparative effectiveness and sustainability of innovative incentive strategies, informed directly by behavioral economics and decision psychology, to promote HIV testing among men and HIV treatment among HIV-infected adults in rural Uganda.
Status | Completed |
Enrollment | 3580 |
Est. completion date | January 3, 2020 |
Est. primary completion date | August 21, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | AIM 1 - TESTING TRIAL Inclusion Criteria: - Male - =18 years - Resident (=6 months) in one of 4 study communities Exclusion Criteria: - Plan to move <6 months from study start AIM 2 - TREATMENT TRIAL Inclusion Criteria: - =18 years - Resident (=6 months) in one of 4 study communities - HIV positive Exclusion Criteria: - Plan to move <6 months from study start AIM 3 - REPEAT TESTING PILOT Inclusion Criteria: - HIV-negative by rapid HIV antibody testing at pilot trial baseline, - Ages 18 - 59 years old, - Attendee of high-risk site of HIV acquisition (e.g. bars, trading centers, etc.) in the region Exclusion Criteria: - Intention to move away from the community in the 3 months from time of recruitment AIM 3 - REPEAT TESTING TRIAL Inclusion Criteria: - HIV-negative by rapid HIV antibody testing at time of recruitment, - Ages 18 - 59 years old, - Reported willingness to retest for HIV in the six months following recruitment, - Sexual risk behavior, defined as at least one of the following self-reported risks in the 12 months prior to recruitment: 1. >1 sexual partner, or 2. known HIV-infected sexual partner, or 3. sexually transmitted infection, or 4. paid or received compensation or gifts for sex. Exclusion Criteria: - Intention to move away from the community for >=4 consecutive months during the six months following recruitment - A history of testing for HIV >=3 times in the 12 months prior to recruitment |
Country | Name | City | State |
---|---|---|---|
Uganda | Infectious Diseases Research Collaboration | Mbarara |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco | Makerere University, National Institute of Mental Health (NIMH), University of Pennsylvania |
Uganda,
Chamie G, Kwarisiima D, Ndyabakira A, Marson K, Camlin CS, Havlir DV, Kamya MR, Thirumurthy H. Financial incentives and deposit contracts to promote HIV retesting in Uganda: A randomized trial. PLoS Med. 2021 May 4;18(5):e1003630. doi: 10.1371/journal.pme — View Citation
Chamie G, Napierala S, Agot K, Thirumurthy H. HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa. Lancet HIV. 2021 Apr;8(4):e225-e236. doi: 10.1016/S2352-3018(21)00023-0. Review. — View Citation
Chamie G, Ndyabakira A, Marson KG, Emperador DM, Kamya MR, Havlir DV, Kwarisiima D, Thirumurthy H. A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda. PLoS One. 2020 May 29;15(5):e0233600. doi: 10.1371/journal.pone.0 — View Citation
Chamie G, Schaffer EM, Ndyabakira A, Emperador DM, Kwarisiima D, Camlin CS, Havlir DV, Kahn JG, Kamya MR, Thirumurthy H. Comparative effectiveness of novel nonmonetary incentives to promote HIV testing. AIDS. 2018 Jul 17;32(11):1443-1451. doi: 10.1097/QAD — View Citation
Kavanagh NM, Schaffer EM, Ndyabakira A, Marson K, Havlir DV, Kamya MR, Kwarisiima D, Chamie G, Thirumurthy H. Planning prompts to promote uptake of HIV services among men: a randomised trial in rural Uganda. BMJ Glob Health. 2020 Nov;5(11). pii: e003390. — View Citation
Marson K, Ndyabakira A, Kwarisiima D, Camlin CS, Kamya MR, Havlir D, Thirumurthy H, Chamie G. HIV retesting and risk behaviors among high-risk, HIV-uninfected adults in Uganda. AIDS Care. 2021 May;33(5):675-681. doi: 10.1080/09540121.2020.1842319. Epub 20 — View Citation
Ndyabakira A, Chamie G, Emperador D, Marson K, Kamya MR, Havlir DV, Kwarisiima D, Thirumurthy H. Men's Beliefs About the Likelihood of Serodiscordance in Couples with an HIV-Positive Partner: Survey Evidence from Rural Uganda. AIDS Behav. 2020 Mar;24(3):9 — View Citation
Ndyabakira A, Getahun M, Byamukama A, Emperador D, Kabageni S, Marson K, Kwarisiima D, Chamie G, Thirumurthy H, Havlir D, Kamya MR, Camlin CS. Leveraging incentives to increase HIV testing uptake among men: qualitative insights from rural Uganda. BMC Publ — View Citation
Schaffer EM, Gonzalez JM, Wheeler SB, Kwarisiima D, Chamie G, Thirumurthy H. Promoting HIV Testing by Men: A Discrete Choice Experiment to Elicit Preferences and Predict Uptake of Community-based Testing in Uganda. Appl Health Econ Health Policy. 2020 Jun — View Citation
Thirumurthy H, Ndyabakira A, Marson K, Emperador D, Kamya M, Havlir D, Kwarisiima D, Chamie G. Financial incentives for achieving and maintaining viral suppression among HIV-positive adults in Uganda: a randomised controlled trial. Lancet HIV. 2019 Mar;6( — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of participants who receive an HIV test at a community health campaign between intervention groups | Aim 1 (IBIS HIV Testing Trial) primary outcome | 6-8 weeks after enrollment; annually | |
Primary | Proportion of participants with HIV RNA <400 copies/mL between intervention groups | Aim 2 (IBIS Treatment Trial) primary outcome | 6 months after enrollment | |
Primary | Proportion of participants randomized to loss aversion trial who make a deposit | Aim 3 Pilot (IBIS Repeat HIV Testing Trial) primary outcome | At enrollment | |
Primary | Proportion of participants who complete all HIV retest visits at study venue | Aim 3 Trial (IBIS Repeat HIV Testing Trial) primary outcome | 6 months | |
Secondary | Proportion of participants who have HIV positive result between intervention groups | Aim 1 (IBIS HIV Testing Trial) secondary outcome | 6-8 weeks after enrollment; annually | |
Secondary | Proportion of participants who receive an HIV test at a testing site between intervention groups | Aim 3 Pilot (IBIS Repeat HIV Testing Trial) secondary outcome | 1-3 months after enrollment | |
Secondary | Proportion of participants who retest for HIV at study venue at 3 months | Aim 3 Trial (IBIS Repeat HIV Testing Trial) secondary outcome | 3-4 months after enrollment | |
Secondary | Proportion of participants who retest for HIV at study venue at 6 months | Aim 3 Trial (IBIS Repeat HIV Testing Trial) secondary outcome | 6-7 months after enrollment | |
Secondary | Proportion of participants who retest for HIV at 3 months among those who made deposits | Aim 3 Trial (IBIS Repeat HIV Testing Trial) secondary outcome | 3-4 months after enrollment | |
Secondary | Proportion of participants who retest for HIV at 6 months among those who made deposits | Aim 3 Trial (IBIS Repeat HIV Testing Trial) secondary outcome | 6-7 months after enrollment | |
Secondary | Cumulative incidence of HIV seroconversion | Aim 3 Trial (IBIS Repeat HIV Testing Trial) secondary outcome | 6-7 months after enrollment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03289676 -
Storytelling Narrative Communication Intervention for Smoking Cessation in Women Living With HIV
|
Phase 1 | |
Completed |
NCT03215901 -
Life Plans Intervention Study
|
N/A | |
Completed |
NCT03268551 -
MEMO-Medical Marijuana and Opioids Study
|
||
Active, not recruiting |
NCT04064567 -
Linking High-Risk Jail Detainees to HIV Pre-Exposure Prophylaxis: PrEP-LINK
|
N/A | |
Completed |
NCT04013295 -
Prize-linked Savings Initiatives for Promoting Better Health and Economic Outcomes in Kenya
|
N/A | |
Recruiting |
NCT04405700 -
Measuring Adverse Pregnancy and Newborn Congenital Outcomes
|
||
Recruiting |
NCT03984136 -
HIV Results Exchange Mechanism on Promoting HIV Testing Among MSM
|
N/A | |
Completed |
NCT02928900 -
Patient Actor Training to Improve HIV Services for Adolescents in Kenya
|
N/A | |
Recruiting |
NCT03268109 -
COGnitive ImpairmenT in Older HIV-infected Patients ≥ 65 Years Old
|
||
Completed |
NCT02797262 -
Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System
|
N/A | |
Completed |
NCT02376582 -
Safety and Immunogenicity Study of a DNA Vaccine Combined With Protein Vaccine Against HIV/AIDS
|
Phase 1 | |
Completed |
NCT01957865 -
Real-Time Antiretroviral Therapy Adherence Intervention in Uganda
|
N/A | |
Terminated |
NCT01443923 -
Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV
|
Phase 4 | |
Completed |
NCT01616940 -
Minority AIDS Initiative Retention and Re-Engagement Project
|
N/A | |
Completed |
NCT01910714 -
Adapting and Evaluating an EBI to Prevent HIV/AIDS Risk Among Apache Youth
|
N/A | |
Completed |
NCT01084421 -
A Computer-Based Parent/Adolescent HIV Communication Intervention for Latinos
|
N/A | |
Completed |
NCT01596322 -
International HIV Antiretroviral Adherence, Resistance and Survival
|
N/A | |
Completed |
NCT03643705 -
A Nurse-led Intervention to Extend the HIV Treatment Cascade for Cardiovascular Disease Prevention
|
N/A | |
Completed |
NCT03923231 -
Pharmacokinetics of Atazanavir in Special Populations
|